Dynamics of platelet functional recovery following a Clopidogrel loading dose in healthy volunteers

被引:22
作者
Price, Matthew J. [1 ]
Teirstein, Paul S. [1 ]
机构
[1] Scripps Clin, Div Cardiovasc Dis, La Jolla, CA 92037 USA
关键词
D O I
10.1016/j.amjcard.2008.02.109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A clopidogrel loading dose before percutaneous coronary intervention may reduce ischemic events but can increase bleeding risk and result in delayed treatment in patients who subsequently require surgical revascularization. The goal of this study was to examine the dynamics of platelet functional recovery after the common clinical scenario of a single 600-mg loading dose of clopidogrel. Fourteen volunteers were administered clopidogrel 600 mg. Platelet reactivity was measured before exposure, 4 hours after exposure, and then daily for 8 days using the VerifyNow P2Y(12) assay. Percentage inhibition (PI) was calculated as the relative change in P2Y(12) reaction units from baseline. One day after clopidogrel, the median PI was 39.9% (range 8.5% to 97.7%). Before day 5, the number of days after exposure was significantly but weakly correlated with PI (Pearson's coefficient = 0.45, R-2 = 0.20, p = 0.001), while most of the variance in PI on each day of recovery was explained by the PI that was observed the previous day (Pearson's coefficient = 0.95, R-2 = 0.92, p < 0.001). The decay in PI over time was exponential, with a common ratio of 17% relative reduction per day (95% confidence interval 10% to 23%). Similar findings were observed when the effect of clopidogrel was defined by residual platelet reactivity or by the adenosine diphosphate-prostaglandin E-1/iso-thrombin receptor-activating peptide ratio. In conclusion, platelet inhibition on each day after a loading dose varies considerably among subjects. The level of inhibition depends less on the number of days after exposure than on the magnitude of initial inhibition after loading. A strategy of individual platelet function monitoring should be examined in patients requiring cardiac surgery after clopidogrel loading. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:790 / 795
页数:6
相关论文
共 20 条
[1]   High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability [J].
Angiolillo, DJ ;
Fernández-Ortiz, A ;
Bernardo, E ;
Ramírez, C ;
Sabaté, M ;
Bañuelos, C ;
Hernández-Antolín, R ;
Escaned, J ;
Moreno, R ;
Alfonso, F ;
Macaya, C .
EUROPEAN HEART JOURNAL, 2004, 25 (21) :1903-1910
[2]   ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) [J].
Braunwald, E ;
Antman, EM ;
Beasley, JW ;
Califf, RM ;
Cheitlin, MD ;
Hochman, JS ;
Jones, RH ;
Kereiakes, D ;
Kupersmith, J ;
Levin, TN ;
Pepine, CJ ;
Schaeffer, JW ;
Smith, EE ;
Steward, DE ;
Theroux, P ;
Gibbons, RJ ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Smith, SC .
CIRCULATION, 2002, 106 (14) :1893-1900
[3]   Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting [J].
Chen, LQ ;
Bracey, AW ;
Radovancevic, R ;
Cooper, JR ;
Collard, CD ;
Vaughn, WK ;
Nussmeier, NA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2004, 128 (03) :425-431
[4]   Platelets [J].
George, JN .
LANCET, 2000, 355 (9214) :1531-1539
[5]   Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J].
Gurbel, PA ;
Bliden, KP ;
Hiatt, BL ;
O'Connor, CM .
CIRCULATION, 2003, 107 (23) :2908-2913
[6]   Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention [J].
Hochholzer, W ;
Trenk, D ;
Frundi, D ;
Blanke, P ;
Fischer, B ;
Andris, K ;
Bestehorn, HP ;
Büttner, HJ ;
Neumann, FJ .
CIRCULATION, 2005, 111 (20) :2560-2564
[7]   Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization [J].
Kandzari, DE ;
Berger, PB ;
Kastrati, A ;
Steinhubl, SR ;
Mehilli, J ;
Dotzer, F ;
ten Berg, JM ;
Neumann, FJ ;
Bollwein, H ;
Dirschinger, J ;
Schömig, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) :2133-2136
[8]   Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? [J].
Kapetanakis, EI ;
Medlam, DA ;
Boyce, SW ;
Haile, E ;
Hill, PC ;
Dullum, MKC ;
Bafi, AS ;
Petro, KR ;
Corso, PJ .
EUROPEAN HEART JOURNAL, 2005, 26 (06) :576-583
[9]   Clopidogrel and bleeding after coronary artery bypass graft surgery [J].
Leong, JY ;
Baker, RA ;
Shah, PJ ;
Cherian, VK ;
Knight, JL .
ANNALS OF THORACIC SURGERY, 2005, 80 (03) :928-933
[10]   Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions [J].
Lepäntalo, A ;
Virtanen, KS ;
Heikkilä, J ;
Wartiovaara, U ;
Lassila, R .
EUROPEAN HEART JOURNAL, 2004, 25 (06) :476-483